Longeveron Inc (LGVN)

Mar 03, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter

Mar 03, 2026

Mar 03, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga

Mar 03, 2026

Mar 03, 2026

Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan

Mar 03, 2026

Mar 01, 2026

LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026

Feb 26, 2026

LGVN: Trial Results Encouraging - Research Tree

Feb 26, 2026

Feb 26, 2026

LGVN Should I Buy - Intellectia AI

Feb 26, 2026

Feb 25, 2026

Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI

Feb 25, 2026

Feb 25, 2026

Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI

Feb 25, 2026

Feb 25, 2026

Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com

Feb 25, 2026

Feb 25, 2026

Longeveron publishes phase 2b stem cell trial results in journal - Investing.com

Feb 25, 2026

Feb 25, 2026

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits

Feb 25, 2026

Feb 25, 2026

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits

Feb 25, 2026

Feb 25, 2026

Longeveron publishes phase 2b stem cell trial results in journal By Investing.com - Investing.com South Africa

Feb 25, 2026

Feb 25, 2026

Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget

Feb 25, 2026

Feb 25, 2026

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times

Feb 25, 2026

Feb 25, 2026

Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan

Feb 25, 2026

Feb 24, 2026

Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN

Feb 24, 2026

Feb 21, 2026

Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn

Feb 21, 2026

Feb 21, 2026

Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World

Feb 21, 2026

Feb 20, 2026

Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru

Feb 20, 2026

Feb 20, 2026

Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World

Feb 20, 2026

Feb 19, 2026

Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn

Feb 19, 2026

Feb 17, 2026

LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 17, 2026

Feb 17, 2026

Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru

Feb 17, 2026

Feb 17, 2026

LGVN: New CEO and Fresh Cost Reductions - Research Tree

Feb 17, 2026

Feb 16, 2026

Longeveron Appoints Stephen Willard as CEO - citybiz

Feb 16, 2026

Feb 16, 2026

Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn

Feb 16, 2026

Feb 16, 2026

Longeveron Appoints New CEO to Lead Pivotal Clinical Trials - National Today

Feb 16, 2026

Feb 15, 2026

Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail

Feb 15, 2026

Feb 14, 2026

Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru

Feb 14, 2026

Feb 14, 2026

Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results - Investing.com Australia

Feb 14, 2026

Feb 13, 2026

Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results By Investing.com - Investing.com South Africa

Feb 13, 2026

Feb 13, 2026

Longeveron Appoints New CEO to Drive Growth - Intellectia AI

Feb 13, 2026

Feb 13, 2026

Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell - Quiver Quantitative

Feb 13, 2026

Feb 13, 2026

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - The Manila Times

Feb 13, 2026

Feb 13, 2026

New Longeveron CEO steps in as pivotal stem cell trial nears - Stock Titan

Feb 13, 2026

Feb 13, 2026

Gains Recap: Is Longeveron Inc. stock supported by strong fundamentalsEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru

Feb 13, 2026

Feb 12, 2026

Is Longeveron Inc. exposed to currency risksQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru

Feb 12, 2026

Feb 11, 2026

How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Feb 11, 2026

Feb 10, 2026

Is Longeveron Inc. still a buy after recent gains2025 Earnings Surprises & Consistent Return Investment Signals - mfd.ru

Feb 10, 2026

Feb 05, 2026

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times

Feb 05, 2026

Feb 05, 2026

Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan

Feb 05, 2026

Feb 04, 2026

Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn

Feb 04, 2026

Jan 31, 2026

Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn

Jan 31, 2026

Jan 29, 2026

Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa

Jan 29, 2026

Jan 29, 2026

Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com

Jan 29, 2026

Jan 29, 2026

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times

Jan 29, 2026

Jan 27, 2026

Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria

Jan 27, 2026

Jan 26, 2026

Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn

Jan 26, 2026

Jan 26, 2026

Published on: 2026-01-27 00:29:51 - baoquankhu1.vn

Jan 26, 2026

Jan 26, 2026

Longeveron Granted FDA Type C Meeting Ahead Of Pivotal ELPIS II Data For HLHS - Nasdaq

Jan 26, 2026

Jan 26, 2026

Longeveron prepares for pivotal HLHS therapy data with FDA meeting - Investing.com

Jan 26, 2026

Jan 26, 2026

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) - The Manila Times

Jan 26, 2026

Jan 26, 2026

Stem cell therapy for rare infant heart defect moves into key FDA talks - Stock Titan

Jan 26, 2026

Jan 22, 2026

Aug Big Picture: Is Longeveron Inc exposed to political riskJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn

Jan 22, 2026

Jan 22, 2026

Revenue Check: What is Longeveron Incs revenue forecastQuarterly Trade Report & Long-Term Capital Growth Ideas - baoquankhu1.vn

Jan 22, 2026

Jan 22, 2026

Buyback Watch: What is the implied volatility of Telefnica Brasil SA Depositary ReceiptJuly 2025 Levels & Real-Time Price Movement Reports - baoquankhu1.vn

Jan 22, 2026

Jan 13, 2026

Portfolio Recap: Can Longeveron Inc continue delivering strong returnsQuarterly Portfolio Review & Comprehensive Market Scan Insights - baoquankhu1.vn

Jan 13, 2026

Jan 13, 2026

Surprises Report: Is Longeveron Inc stock a defensive play in 2025Quarterly Market Review & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ

Jan 13, 2026